Number of Shares and Voting Rights of ADOCIA as of September 30th, 2021
October 12 2021 - 11:00AM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA, a French société anonyme (corporation), 115, avenue
Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a
clinical stage biopharmaceutical company focused on treatment of
diabetes, obesity and metabolic diseases with innovative
formulations of approved proteins, releases its total number of
outstanding shares as well as its voting rights as of September
30th, 2021.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting rights (2)
September
09/30/2021
7 029 529
9 800 992
9 765 218
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring six clinical-stage products and several
pre-clinical products. The proprietary BioChaperone® technological
platform is designed to enhance the effectiveness and/or safety of
therapeutic proteins while making them easier for patients to use.
Adocia customizes BioChaperone® to each protein for a given
application.
Adocia’s clinical pipeline includes five novel insulin
formulations for the treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and two combinations of a
prandial insulin with amylin analog pramlintide (M1Pram and
BioChaperone® LisPram). The clinical pipeline also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: a combination of rapid acting insulin
analogs and pramlintide (BioChaperone® AsPram), a combination of
insulin glargine with GLP-1 receptor agonists (BioChaperone®
Glargine Liraglutide). In addition, there are two bi-hormonal
products for the treatment of obesity: a combination of glucagon
and exenatide (BioChaperone® GluExe) and a combination of
pramlintide and exenatide (PramExe).
Adocia recently added a preclinical program to its pipeline with
a cell therapy initiative focused on the development of a hydrogel
scaffold for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the Universal Registration
Document that was filed with the French Autorité des marchés
financiers on April 20, 2021 (a copy of which is available at
www.adocia.com), in particular uncertainties that are linked to
research and development, future clinical data, analyses, and the
evolution of the economic context, the financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not considered as material by Adocia as of this
day. The occurrence of all or part of such risks could cause that
actual results, financial conditions, performances, or achievements
of Adocia be materially different from those mentioned in the
forward-looking statements. This press release and the information
contained herein do not constitute an offer to sell or the
solicitation of an offer to buy Adocia’s shares in any
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012005851/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu Ph: +49 89 210
228 0
The Ruth Group Adocia Investor Relations USA Brett
Mermelstein Senior Account Executive
bmermelstein@theruthgroup.com Ph.: +1 267 639 0721
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024